close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytek Biosciences, Inc. - Common Stock (NQ:CTKB)

3.970 +0.010 (+0.25%)
Streaming Delayed Price Updated: 1:56 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytek Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Gold Down Over 2%; CVS Health Shares Jump After Q3 Results ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Mercury Systems Posts Strong Results, Joins ArcBest, Tesla, Kennametal, Qualys And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Preview: Cytek Biosciences's Earnings ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Cytek Biosciences ↗
 
Via Benzinga
News headline image
Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe
Industry Leaders to Explore Cytek’s Advanced Cell Analysis Solutions at ICCS and ESCCA 
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
Certification Emphasizes Unwavering Commitment to Quality and Is an Essential Step for U.S. Clinical Market Entry 
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
CTKB Stock Earnings: Cytek Biosciences Misses EPS, Misses Revenue for Q2 2024 ↗
CTKB stock results show that Cytek Biosciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm
Expanding Capabilities and Streamlining Experimental Workflows 
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences Announces $50 Million Stock Repurchase Program
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
New Enhanced Small Particle (ESP™) Detection Option for Cytek Northern Lights™ and Cytek Aurora™ Systems Expands Capabilities of Small Particle Research 
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
CTKB Stock Earnings: Cytek Biosciences Misses EPS, Beats Revenue for Q1 2024 ↗
CTKB stock results show that Cytek Biosciences missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Cytek Biosciences Reports First Quarter 2024 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
Company to Conduct Educational Workshops and Tutorials at CYTO and AAI’s IMMUNOLOGY2024 
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
CTKB Stock Earnings: Cytek Biosciences Beats Revenue for Q4 2023 ↗
CTKB stock results show that Cytek Biosciences beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Cytek® Biosciences Names William McCombe Chief Financial Officer
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday. 
Via Benzinga
Topics Stocks
News headline image
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
News headline image
Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences to Participate in Upcoming Investor Conferences
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
Cytek’s Cutting-Edge Spectral Flow Cytometry Technology, Specialized Staff, Tools and Solutions Set New Benchmarks for Cell Analysis 
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry
New System Saves Time and Resources, Improves Efficiency and Accuracy 
From Cytek Biosciences, Inc.
Via GlobeNewswire
News headline image
Cytek's Full Spectrum Technology Stands Out In Cell Analysis Market, Bullish Analyst Says ↗
Stephens initiated coverage on Cytek Biosciences Inc (NASDAQ: CTKB), a manufacturer and supplier of flow cytometry products and services.  
Via Benzinga
Topics Supply Chain
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today